Vraylar vs Auvelity
A side-by-side look at two mental health medications advertised on TV. Informational only — not medical advice.
| US Vraylar | US Auvelity | |
|---|---|---|
| Generic name | cariprazine | dextromethorphan/bupropion |
| Drug class | Atypical Antipsychotic | NMDA Antagonist / Aminoketone Combination |
| Treats | Bipolar disorder, schizophrenia, depression (add-on) | Major depressive disorder |
| Category | Mental Health | Mental Health |
| Manufacturer | AbbVie | Axsome Therapeutics |
| Year approved | 2015 | 2022 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $200M | $50M |
| Common side effects | Movement disorders, Drowsiness, Restlessness, Weight changes | Dizziness, Headache, Diarrhea, Sleepiness |
Frequently asked questions
Is Vraylar or Auvelity better?
Neither is universally "better." Vraylar (cariprazine) and Auvelity (dextromethorphan/bupropion) are both used for mental health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Vraylar and Auvelity?
Vraylar is a Atypical Antipsychotic made by AbbVie, while Auvelity is a NMDA Antagonist / Aminoketone Combination made by Axsome Therapeutics. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Vraylar has the larger estimated TV advertising budget of the two.